Option chain shows key data for CV Sciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for CV Sciences.

CV Sciences (OTC:CVSI) Stock, Option Chain

CV Sciences

CV Sciences Inc develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol. The Company sells its products under tradenames, such as +PlusCBD and PlusCBD Pet. The Company's products are sold in a variety of market sectors including nutraceutical, beauty care, and specialty foods. The company's hemp-based products are predominantly sold in North America and primarily in the retail space. The company generates revenue from Retail Sales and E-Commerce sales of its product.

signs some cannabis bill (RazorMax and ganjaspliffstoreuk to Pixabay)(2)

Cannabis

News

CVSI

CV Sciences, Inc. (OTCQB: CVSI) a hemp-focused wellness company announced on Thursday it&#39;s acquiring Extract Labs, Inc., a manufacturer and distributor of premium cannabinoid products including gummies, topicals and tinctures. Extract Labs&#39; branded products are sold through a range of sales channels from business-to-business (B2B) to business-to-consumer (B2C).

Hemp-Focused CV Sciences Expands Via New Cannabis Acquisition, Here&#39;s What Investors Need To Know

Cannabis stocks

Earnings

CV Sciences Q3 2024 financial results: stable $3.9M revenue, improved 46% gross margin, new products, and nearing cash flow break-even.

CV Sciences Q3: Revenue Stable Amid New Launches, Financing

ibrahim-rifath-OApHds2yEGQ-unsplash(4)

CV Sciences, Inc. (OTCQB: CVSI) a hemp-focused wellness company announced on Tuesday its financial results for the second quarter that ended June 30, 2024, revealing a flat revenue year-over-year at $4 million for the period. &#34;Revenues for our core business remained stable at $4 million in the second quarter of 2024 despite a challenging environment,&#34; Joseph Dowling, CEO of CV Sciences, said. &#34;With our recently completed acquisitions and new product innovations, we are planning to grow our revenue in the second half of 2024. Our 47.0% gross margin in the second quarter of 2024 is our best gross margin in the last 13 quarters.&#34;

Hemp-Focused CV Sciences Reports Flat Revenue And Over 8% YoY Increase In Gross Profit In Q2

CV Sciences Inc

Small Cap

Press Releases

CV SCIENCES, INC. ACQUIRES ELEVATED SOFTGELS, A FLEXIBLE, LOW-MOQ, NUTRACEUTICAL MANUFACTURER

CV Sciences, Inc. Reports First Quarter 2024 Financial Results

CV Sciences, Inc. To Announce Second Quarter 2024 Results On August 13, 2024

CV Sciences, Inc. Reports Second Quarter 2024 Financial Results

CV Sciences Launches +PlusHLTH, a New Line of Cannabinoid-Free Supplements

CV Sciences, Inc. To Announce Third Quarter 2024 Results On November 14, 2024

CV Sciences, Inc. Reports Third Quarter 2024 Financial Results

CV Sciences, Inc. Enters Into Definitive Agreement to Acquire Extract Labs

CV Sciences Unveils New Aura Collection THC Fizz Tablets

CV Sciences, Inc. To Announce Year End and Fourth Quarter 2024 Results On March 27, 2025

Comments

CV Sciences

CV Sciences (CVSI) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga